Company news
Tvardi Therapeutics, Inc. news in 2022
Tvardi Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Cara Therapeutics Reports Third Quarter 2022 Financial Results
November 6, 2022
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
November 2, 2022
Cara Therapeutics to Present at Upcoming Investor Conferences
November 1, 2022
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
October 23, 2022
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics
October 9, 2022
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
September 27, 2022
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
September 11, 2022
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
September 7, 2022
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022
August 23, 2022
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress
August 21, 2022
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
August 18, 2022
Cara Therapeutics Reports Second Quarter 2022 Financial Results
August 7, 2022
Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 2, 2022
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022
July 31, 2022
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica
June 29, 2022
Cara Therapeutics Reports First Quarter 2022 Financial Results
May 8, 2022
Cara Therapeutics to Present at May Investor Conferences
May 2, 2022
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
April 28, 2022
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
April 27, 2022
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 4, 2022
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022
April 3, 2022
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus
March 27, 2022
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
March 7, 2022
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
February 27, 2022
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
February 21, 2022
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
February 17, 2022
Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
January 9, 2022
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 2, 2022